10 August 2026
Latham & Watkins Advises on Latigo Biotherapeutics’ Upsized US$345.6 Million Initial Public Offering
Advising firms
Deal team
5 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | Capital Markets | New York |
| Sandy Kugbei Lead | Latham & Watkins LLP | Partner | Capital Markets | New York |
| Alison Haggerty Lead | Latham & Watkins LLP | Partner | Capital Markets | New York |
| Vanessa Hillabrand | Latham & Watkins LLP | Associate | Capital Markets | New York |
| Helen Zhang | Latham & Watkins LLP | Associate | Capital Markets | New York |
2 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 346m (US$345.6 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- Latigo Biotherapeutics, Inc. (Issuer)